Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast

212. Long-Term 52-Week Results of Palace 3, A Phase 3, Randomized, Controlled Trial of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis and Current Skin Involvement

(2017) Christopher J. Edwards et al.   RHEUMATOLOGY

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

(2015) C. Paul et al.   BRITISH JOURNAL OF DERMATOLOGY

Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis

(2015) A. Kavanaugh et al.   JOURNAL OF RHEUMATOLOGY

Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study

(2015) Gulen Hatemi et al.   NEW ENGLAND JOURNAL OF MEDICINE

SAT0389 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from the Palace 4 Phase 3, Randomized, Controlled Trial

(2014) C. Edwards et al.   ANNALS OF THE RHEUMATIC DISEASES

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

(2014) P.H. Schafer et al.   CELLULAR SIGNALLING

Apremilast mechanism of action and application to psoriasis and psoriatic arthritis

(2012) Peter Schafer   BIOCHEMICAL PHARMACOLOGY

Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study

(2012) K.A. Papp et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

(2012) Kim Papp et al.   LANCET

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)

(2011) J. Barker et al.   BRITISH JOURNAL OF DERMATOLOGY

A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis

(2011) Kristian Reich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Psoriasis: depression, anxiety, smoking, and drinking habits

(2010) Jennifer Hayes et al.   Dermatologic Therapy

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

(2009) PH Schafer et al.   BRITISH JOURNAL OF PHARMACOLOGY

Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor

(2009) Hon-Wah Man et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cyclic AMP

(2008) Carlos H. Serezani et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast

(2008) A. B. Gottlieb et al.   CURRENT MEDICAL RESEARCH AND OPINION